Search openICPSR


Find and share social, behavioral, and health sciences research data.

  • Search terms can be anywhere in the study: title, description, variables, etc.
  • Because our holdings are large, we recommend using at least two query terms:
    rural economy
    home ownership
    higher education
    ghana adolescents
  • Keywords help delimit the breadth of results. Therefore, use as many as required to achieve your desired results:
    elementary education federal funding
  • Our search will find studies with derivative expressions of your query terms: A search for "nation" will find results containing "national"
  • Use quotes to search for an exact expression:
    "social mobility"
  • You can combine exact expressions with loose terms:
    "united states" inmates
  • Exclude results by using a MINUS sign:
    elections -sweden -germany
    elections -sweden -germany
  • On the results page, you will be able to sort and filter to further refine results.
  • Please note that your search queries only openICPSR data holdings.
CLOSE
Name File Type Size Last Modified
  AEJPol-2016-0035-Replication 10/13/2019 05:24:AM
LICENSE.txt text/plain 14.6 KB 10/13/2019 01:26:AM

Project Citation: 

Yurukoglu, Ali, Liebman, Eli, and Ridley, David B. Replication data for: The Role of Government Reimbursement in Drug Shortages. Nashville, TN: American Economic Association [publisher], 2017. Ann Arbor, MI: Inter-university Consortium for Political and Social Research [distributor], 2019-10-13. https://doi.org/10.3886/E114681V1

Project Description

Summary:  View help for Summary Beginning in the mid-2000s, the incidence of drug shortages rose, especially for generic injectable drugs such as anesthetics and chemotherapy treatments. We examine whether reimbursement changes contributed to the shortages, focusing on a reduction in Medicare Part B reimbursement to providers for drugs. We hypothesize that lower reimbursement put downward pressure on manufacturers' prices, which reduced manufacturers' incentives to invest in capacity, reliability, and new launches. We show that after the policy change, shortages rose more for drugs with higher shares of patients insured by Medicare, greater decreases in provider reimbursement, and greater decreases in manufacturer prices.

Scope of Project

JEL Classification:  View help for JEL Classification
      H51 National Government Expenditures and Health
      I18 Health: Government Policy; Regulation; Public Health
      L10 Market Structure, Firm Strategy, and Market Performance: General
      L65 Chemicals; Rubber; Drugs; Biotechnology; Plastics


Related Publications

Published Versions

Export Metadata

Report a Problem

Found a serious problem with the data, such as disclosure risk or copyrighted content? Let us know.

This material is distributed exactly as it arrived from the data depositor. ICPSR has not checked or processed this material. Users should consult the investigator(s) if further information is desired.